Accessing our website tells us you are happy to receive all our cookies. However you can change your cookie settings at any time.

Privacy & Cookies

You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Our Financial Highlights for 2018

2018 delivered continued strong performance from our International Star brands, led by KELO-COTE™.


For the first time, our overseas sales exceeded those from the UK market.

Nizoral acquired from Johnson & Johnson for the Asia Pacific region in June 2018 for £60m; revenues in line with expectations and integration progressing well.

Vamousse integration completed and Alliance subsidiary fully established in the US; Vamousse revenues up 16% year on year under Alliance management.

To view in detail click here to download our 2018 Annual Report.

currently counter number sum counter number

See-through revenue*

currently counter number sum counter number

Underlying profit before tax

currently counter number sum counter number

Underlying adjusted basic EPS*

currently counter number sum counter number

Statutory revenue

currently counter number sum counter number

Reported profit before tax

currently counter number sum counter number

Reported basic EPS

Please view our five year financial summary below

Five Year Summary
Year ended 31 December 2014 £mYear ended 31 December 2015 £mYear ended 31 December 2016 £mYear ended 31 December 2017 £m restatedYear ended 31 December 2018 £m
Revenue43.548.397.5101.6118.2
Operating profit before non-underlying items11.810.625.625.828.9
Non-underlying operating items0.6(6.3)-4.4(5.3)
Operating profit11.217.025.630.223.7
Profit before tax before non-underlying items10.811.022.223.928.1
Profit before tax after non-underlying items10.215.222.228.322.8
Intangible assets88.9259.9264.8278.6335.2
Tangible assets0.41.01.85.77.6
Current assets15.727.849.349.158.7
Current liabilities11.431.850.361.491.7
Equity70.8162.4179.3203.1252.2
Average shares in issue (millions)264.1272.7469.4473.8497.2
Shares in issue at period end (millions)264.1468.2472.6475.0518.2
Earnings per share – basic (p)3.174.653.856.083.69
Earnings per share – adjusted underlying basic (p)3.363.693.694.054.54

* Non-IFRS alternative performance measures (see note 34). See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15
** 2017 comparatives restated following the adoption of IFRS 15 Revenue from Contracts with Customers and IFRS 16 Leases